Related Experiment Video

Updated: Jun 21, 2026

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Matrix metalloproteinase 1 promoter polymorphisms and risk of myocardial infarction: a case-control study in a

Pablo Román-García1, Eliecer Coto, Julián R Reguero

  • 1Servicio de Metabolismo Oseo y Mineral, Hospital Universitario Central de Asturias, Oviedo, Spain.

Coronary Artery Disease
|July 22, 2009
PubMed
Abstract

Insights

Matrix metalloproteinase-1 (MMP-1) promoter polymorphisms are linked to early myocardial infarction (MI) risk in Spanish male smokers. Specific MMP-1 gene variants influence susceptibility to this cardiovascular disease.

Area of Science:

  • Cardiovascular Genetics
  • Molecular Biology
  • Atherosclerosis Research

Background:

  • Atherosclerosis, leading to myocardial infarction (MI), involves inherited and acquired risk factors.
  • Matrix metalloproteinases (MMPs), particularly MMP-1, are implicated in atherosclerotic lesion development.
  • Functional polymorphisms in the MMP-1 gene have been associated with MI risk.

Purpose of the Study:

  • To investigate the association between MMP-1 promoter polymorphisms and early-onset MI.
  • To analyze specific MMP-1 gene variants in a Spanish cohort of male smokers.

Main Methods:

  • A case-control study involving 261 male patients with early MI and 194 healthy male smokers.
  • Genotyping of three MMP-1 promoter polymorphisms (-1607 1G/2G, -519 A/G, -340 T/C) using PCR-restriction fragment length polymorphism.
  • Statistical comparison of allelic, genotypic, and haplotypic frequencies between cases and controls.

Main Results:

  • No significant differences in individual polymorphism frequencies between MI patients and controls.
  • Linkage disequilibrium observed between the -1607 1G/2G and -519 A/G variants.
  • Significant associations found for specific MMP-1 haplotypes with early MI risk: 2G(-1607)-G(-519)-T(-340) (OR=2.40) and 1G(-1607)-G(-519)-T(-340) (OR=0.68).

Conclusions:

  • MMP-1 promoter polymorphisms are associated with the risk of developing early myocardial infarction.
  • Specific MMP-1 haplotypes contribute to varying risks of early MI in Spanish male smokers.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...